久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Atox Bio Announces Exercise by BARDA of Next Option Period for NSTI Treatment americanpharmaceuticalreview
    June 20, 2019
    Atox Bio announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).
  • Atox Bio Announces Chief Commercial Officer Appointment americanpharmaceuticalreview
    February 18, 2019
    Atox Bio announced the appointment of Robert Greif as Chief Commercial Officer. In this newly created position, Greif will be responsible for building the commercial organization and pre-commercial activities for Reltecimod....
PharmaSources Customer Service